Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 31.65% is in line with its 5-year average of 33.61%, around the middle of its 5-year range (26.44%–39.55%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.87% below its 12-month average of 32.25%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 31.65%.
DEBT TO ASSETS RATIO
31.65%
DEBT TO ASSETS RATIO AVG TTM
32.25%
DEBT TO ASSETS RATIO AVG 3Y
34.05%
DEBT TO ASSETS RATIO AVG 5Y
33.61%
DEBT TO ASSETS RATIO AVG 10Y
28.47%
DEBT TO ASSETS RATIO AVG 15Y
25.13%
DEBT TO ASSETS RATIO AVG 20Y
22.41%
CURRENT VS TTM AVG
-1.87%
CURRENT VS 3Y AVG
-7.06%
CURRENT VS 5Y AVG
-5.84%
CURRENT VS 10Y AVG
+11.17%
CURRENT VS 15Y AVG
+25.95%
CURRENT VS 20Y AVG
+41.23%
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 822 covered companies
CURRENT VS SECTOR MEDIAN
+35065.88%
vs the sector median at left
Bruker Corporation
Market Cap
$8.98B
Debt to Assets Ratio
31.65%
TTM Avg
32.25%
3Y Avg
34.05%
5Y Avg
33.61%
Market Cap
$8.97B
Debt to Assets Ratio
0.29%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$8.81B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$8.69B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$8.57B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.55B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bruker Corporation (BRKRP) | $8.98B | 31.65% | 32.25% | 34.05% | 33.61% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | 0.29% | N/A | N/A | N/A |
| Protagonist Therapeutics, Inc. (PTGX)vs › | $8.81B | 0.01% | N/A | N/A | N/A |
| Bruker Corporation (BRKR)vs › | $9.33B | 0.32% | N/A | N/A | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.69B | 0.41% | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.37B | 0.30% | N/A | N/A | N/A |
| Vaxcyte, Inc. (PCVX)vs › | $9.41B | 0.04% | N/A | N/A | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.57B | 0.05% | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.55B | 0.01% | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.40B | 0.04% | N/A | N/A | N/A |
Debt/Assets
31.6%
Debt/Equity
0.80
Current Ratio
1.85
Interest Coverage
3.9x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 31.65% |
| 2026-03-31 | 27.26% |
| 2025-12-31 | 32.73% |
| 2025-09-30 | 31.21% |
| 2025-06-30 | 38.41% |
| 2025-03-31 | 35.63% |
| 2024-12-31 | 38.67% |
| 2024-09-30 | 39.55% |
| 2024-06-30 | 38.45% |
| 2024-03-31 | 32.49% |
| 2023-12-31 | 32.46% |
| 2023-09-30 | 31.93% |
| 2023-06-30 | 32.24% |
| 2023-03-31 | 32.65% |
| 2022-12-31 | 35.17% |
| 2022-09-30 | 34.58% |
| 2022-06-30 | 35.01% |
| 2022-03-31 | 34.26% |
| 2021-12-31 | 38.19% |
| 2021-09-30 | 26.44% |
| 2021-06-30 | 26.86% |
| 2021-03-31 | 27.16% |
| 2020-12-31 | 29.94% |
| 2020-09-30 | 30.28% |
| 2020-06-30 | 36.26% |
| 2020-03-31 | 35.62% |
| 2019-12-31 | 31.78% |
| 2019-09-30 | 24.21% |
| 2019-06-30 | 23.39% |
| 2019-03-31 | 17.52% |
| 2018-12-31 | 16.02% |
| 2018-09-30 | 12.74% |
| 2018-06-30 | 12.21% |
| 2018-03-31 | 12.05% |
| 2017-12-31 | 21.33% |
| 2017-09-30 | 24.50% |
| 2017-06-30 | 22.52% |
| 2017-03-31 | 20.91% |
| 2016-12-31 | 22.71% |
| 2016-09-30 | 20.30% |
| 2016-06-30 | 19.94% |
| 2016-03-31 | 17.37% |
| 2015-12-31 | 15.41% |
| 2015-09-30 | 20.15% |
| 2015-06-30 | 20.03% |
| 2015-03-31 | 20.00% |
| 2014-12-31 | 19.04% |
| 2014-09-30 | 18.59% |
| 2014-06-30 | 17.75% |
| 2014-03-31 | 17.50% |
| 2013-12-31 | 17.85% |
| 2013-09-30 | 18.37% |
| 2013-06-30 | 18.68% |
| 2013-03-31 | 18.58% |
| 2012-12-31 | 18.16% |
| 2012-09-30 | 18.72% |
| 2012-06-30 | 18.34% |
| 2012-03-31 | 17.78% |
| 2011-12-31 | 17.72% |
| 2011-09-30 | 18.64% |
| 2011-06-30 | 16.93% |
| 2011-03-31 | 18.19% |
| 2010-12-31 | 19.42% |
| 2010-09-30 | 9.51% |
| 2010-06-30 | 11.11% |
| 2010-03-31 | 11.49% |
| 2009-12-31 | 11.75% |
| 2009-09-30 | 13.46% |
| 2009-06-30 | 15.70% |
| 2009-03-31 | 19.22% |
| 2008-12-31 | 20.05% |
| 2008-09-30 | 19.86% |
| 2008-06-30 | 20.67% |
| 2008-03-31 | 30.24% |
| 2007-12-31 | 6.89% |
| 2007-09-30 | 7.84% |
| 2007-06-30 | 7.16% |
| 2007-03-31 | 7.42% |
| 2006-12-31 | 10.32% |
| 2006-09-30 | 13.78% |
| 2006-06-30 | 8.32% |
| 2006-03-31 | 8.34% |
| 2005-12-31 | 8.15% |
| 2005-09-30 | 9.33% |
| 2005-06-30 | 9.48% |
| 2005-03-31 | 11.43% |
| 2004-12-31 | 10.76% |
| 2004-09-30 | 12.79% |
| 2004-06-30 | 13.35% |
| 2004-03-31 | 14.27% |
| 2003-12-31 | 12.81% |
| 2003-09-30 | 12.39% |
| 2003-06-30 | 14.13% |
| 2003-03-31 | 13.94% |
| 2002-12-31 | 11.52% |
| 2002-09-30 | 10.06% |
